肠道微生物群作为治疗帕金森病益生菌药物的来源
Elena U Poluektova1, Alla Stavrovskaya2, Anastasia Pavlova2
1Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow 119991, Russia.
International journal of molecular sciences
|October 16, 2025
概括
益生菌在通过影响肠-大脑轴来治疗帕金森病 (PD) 方面表现有前途. 本综述探讨了它们作为PD的支持性疗法的潜力,与PD研究中的肠道微生物群和AI一起.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,具有运动和非运动症状.
- 肠道微生物群的变化和肠-大脑轴的失调与PD的发病有关.
- 目前的PD治疗专注于症状管理,缺乏疾病修饰的选择.
研究的目的:
- 审查目前关于帕金森病中益生菌效应的数据.
- 要突出益生菌在调节PD病理生理学中的作用.
- 讨论益生菌作为PD的潜在辅助疗法.
主要方法:
- 对PD中益生菌的动物模型和临床研究的审查.
- 在PD中分析肠-大脑轴和肠道微生物群.
- 包括PD临床表现和AI在PD建模中的部分.
主要成果:
- 益生菌在调节PD病理生理学方面显示出潜力.
- 来自动物模型和临床研究的证据支持益生菌的有效性.
- 益生菌可以作为帕金森病的辅助治疗剂.
结论:
- 益生菌代表了对帕金森病的有希望的治疗途径.
- 需要进一步研究功能性肠道细菌,包括益生菌.
- 将益生菌纳入PD管理可能会带来全面的好处.
相关概念视频
Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Microorganisms in Medicine and Therapeutics
936
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
936
Drugs for Treatment of Diarrhea-Predominant IBS
625
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
625
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
419
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
419
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K


